<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2091">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04365322</url>
  </required_header>
  <id_info>
    <org_study_id>2020/502</org_study_id>
    <nct_id>NCT04365322</nct_id>
  </id_info>
  <brief_title>Study of Specific Viral Immune Responses Induced by SARS-CoV-2 (COVID-19)</brief_title>
  <acronym>COV-CREM</acronym>
  <official_title>Étude Des réponses Immunitaires Lymphocytaires spécifiques Chez Des Patients infectés Par le Virus SARS-CoV-2 : Caractéristiques Des Réponses Effectrices et Mémoires</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SARS-CoV-2, has caused an international outbreak of respiratory illness termed Covid-19. The
      investigators used peptides derived from SARS-CoV-2 virus, to study viral-specific immune
      responses. COV-CREM is a French prospective monocentric study that will evaluate
      viral-specific cell responses in positive patients for SARS-CoV-2 on the basis of (RT-PCR)
      assay performed in respiratory tract sample tested by our local Center for Disease Control.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Anticipated">April 20, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Specific immune responses</measure>
    <time_frame>During COVID-19 infection or one month after COVID-19 infection</time_frame>
    <description>Intensity and diversity of immune responses specific for SARS-COV-2</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Severe COVID-19 infection</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Light to moderate COVID-19 infection</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cancer patients with COVID-19 infection</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Additional biological samples</intervention_name>
    <description>Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected.</description>
    <arm_group_label>Cancer patients with COVID-19 infection</arm_group_label>
    <arm_group_label>Light to moderate COVID-19 infection</arm_group_label>
    <arm_group_label>Severe COVID-19 infection</arm_group_label>
    <other_name>Additional blood samples will be realized as part of the care</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with COVID-19 or convalescent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COVID-19 PCR positive,

          -  Hospitalized patients with illness of any duration, and/or SpO2 ≤ 92% on room air.

          -  Cohorte C : patients with cancer (hematological malignancies and solid tumors).

        Exclusion Criteria:

          -  Refusal to participate,

          -  Any immunosuppressive therapy (i.e. corticosteroids &gt;10mg of hydrocortisone or
             equivalent dose) within 14 days before the planned start of study,

          -  Active or chronic hepatitis B or C and/or HIV positive (HIV 1/2 antibodies patients),
             or a known history of active Tuberculosis bacillus,

          -  Active autoimmune disease that required a systemic treatment, with the following
             exceptions:

               -  Patients with a history of autoimmune-related hypothyroidism who are on thyroid
                  replacement hormone are eligible for the study,

               -  Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen
                  are eligible for the study,

          -  Prior allogeneic bone marrow transplantation or prior solid organ transplantation,

          -  Patients currently exposed to chemotherapy, anti-tumor immunotherapy as anti-PD-1,
             anti-PD-L1, or anti-CTLA4 agent or any immune therapy or biotherapy (except for
             patients in cohort C),

          -  Previous prescribing of biotherapy or treatment for the management of COVID-19 is not
             an exclusion criterion,

          -  Patient under guardianship, curatorship or under the protection of justice.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marie KROEMER, PharmD PhD</last_name>
    <phone>0370632281</phone>
    <email>mkroemer@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kevin BOUILLER, MD</last_name>
    <email>kbouiller@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie KROEMER, PharmD PhD</last_name>
      <email>mkroemer@chu-besancon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Kevin BOUILLER, MD</last_name>
      <email>kbouiller@chu-besancon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 25, 2020</study_first_submitted>
  <study_first_submitted_qc>April 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

